Infections
21/09/2020 13:27
Sept 21 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH DEVELOPING TRUE HUMAN ANTIBODY COMBINATION AS
CANDIDATE
TREATMENT FOR INFLUENZA-COVID-19 CO-INFECTIONS
* XBIOTECH INC - DEVELOPING NEW CANDIDATE THERAPY CALLED
FLUVID
FOR TREATING ILLNESS CAUSED BY COMBINED INFECTIONS WITH
INFLUENZA AND COVID-19
* XBIOTECH INC - FLUVID WILL CONTAIN IH201 AND IH302
ANTIBODIES
ALONG WITH COMPANY'S ANTI-COVID-19 ANTIBODY
Source text for Eikon: ID:nGNX9GjhMF
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke